Comparison of Cabergoline with Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection:A randomized trial

a:4:{s:9:"Objective";s:192:"The aim of the present study was to compare Quinagolide with Cabergoline in prevention of ovarian hyper stimulation syndrome among high risk women undergoing intra cytoplasmic sperm injection.";s:19:"MaterialsAndMethods";s:948:"Material and Methods: This Randomized clinical trial study was performed from March 2015 to February 2017. One hundred and twenty six women undergoing ICSI and at high risk of developing ovarian hyperstimulation syndrome (>20follicles>12mm developed), were randomized into two groups. The first group received Cabergoline 0.5mg and the second group received Quinagolide 75mg every day for 7 days commencing on the day of GnRH agonist administration. Then ovarian hyperstimulation syndrome symptoms as well as its severity were assessed according to standard definition 3and 6 days after GnRH agonist administration. Ascites was determined by trans-vaginal ultrasound. Other secondary points were number of oocytes, number of embryos and their quality. Quantitative and qualitative data were analyzed using Student's t test, and Chi-square or fisher’s exact test, respectively. A P-value of less than 0.05 was considered statistically significant.";s:7:"Results";s:734:"Results: The incidence of severe ovarian hyperstimulation syndrome in the Quinagolide group was 3.1% while it was 15.8% in Cabergoline group (p